Issues related to prescription drug pricing and value Prescription drug manufacturing and supply chains Issues related to 340B program Issues related to tax and tariffs Issues related to Intellectual Property Issues related to Inflation Reduction Act
2025 · 2nd Quarter (Apr 1 - June 30)
BOEHRINGER INGELHEIM USA CORPORATION
Filed by BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC.
Open official filingSource-reported fields
Filing overview
- Type
- 2nd Quarter - Report
- Posted
- Jul 21, 2025
- Income
- Not reported
- Expenses
- $990,000.00
- Registrant
- BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
- Filing UUID
- 6d7bafae-cfe0-493e-ae9e-88c4556106b0
- Termination date
- Not reported
Expense method: A
Literal source text
Lobbying issues and bill citations
Education about chronic kidney disease and Medicare screening guidelines Issues related to Medicare Part D redesign Issues related to prescription drug pricing and value Issues regarding implementation of the Inflation Reduction Act, including H.R. 1492/S.832 - EPIC Act of 2025 Issues related to the Treat and Reduce Obesity Act The Access to Prescription Digital Therapeutic Act Issues related to Most Favored Nation Proposals
Issues related to Animal Health Issues related to One Health Issues Related to Compounding Animal Drugs from Bulk Substances Far, Food and National Security Act of 2024 (H.R. 8467) Foreign Animal Disease Prevention Surveillance and Rapid Response Act of 2023 (H.R. 3419/S.1666)
Literal federal measure citations: H.R. 8467, H.R. 3419, S.1666
Issues related to FY2026 Appropriations
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.